Further, in breast cancer, FGFR1-amplified cell lines express higher levels of FGFR1 protein and are more sensitive to FGFR inhibition with the pan-kinase inhibitor, brivanib, compared to cell lines with normal FGFR1 or FGFR1 deletion [37]. This evidence concerns the gene FGFR1 and breast carcinoma.